Táblázat minta LI – Izotóp Intézet

For Renal Studies

Table: Cold kits – For Renal Studies

In vivo kit

Product Code

ATC code

Marketing Authorisation No.

For preparation of

Active ingredient

Content/vial

Excipients

Indications

Activity for labelling vial

Vials per kit

Recommended doses

Shelf life

Storage

SPC

DMSA 1.5 mg

Tc-IK-7

V09CA02

OGYI-T9245/01

Technetium (^99mTc) succimer injection

Dimercaptosuccinic acid

1.5 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Calcium gluconate
- Kidney scintigraphy, static kidney imaging, localisation of the
  kidneys with imaging
- Determination of the functional mass of the kidney
- Determination of the relative function ratio (percentage) of the
  left and right kidneys
1.0–1.8 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months
after radiolabelling: 8 h

2-8°C
after radiolabelling: ≤ 25°C
DTPA 9 mg

Tc-IK-8

V09CA01

OGYI-T-9244/01

Technetium (^99mTc) pentate injection

Diethylenetriamino pentaacetic acid

9.0 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Sodium chloride
- Dynamic studies of kidney, determination of kidney perfusion,
  glomerural filtration rate, total and partial kidney function
- Examination of the cerebral blood circulation
- Examination of the gastrointestinal tract by using labelled
  foodstuff or drink
- Examination of liquor circulation
0.8–2.4 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months
after radiolabelling: 8 h

≤ 25°C
after radiolabelling: ≤ 25°C
EC 2 mg

Tc-IK-25

V09CA

OGYI-T-9141/01

Technetium (^99mTc) EC injection

Ethylene-dicysteine

2.0 mg
Vial A
- Disodium hydrogen phosphate dihydrate
- Mannitol
- Ascorbic acid
- Sodium edetate
Vial B
- Stannous chloride dihydrate
- Ascorbic acid
- Tartaric acid
Vial C
- Potassium dihydrogen phosphate
- Ascorbic acid
- Dynamic studies of kidney for renal tubular function
0.8–1.6 GBq

3 x 4 injection vials

See in the Summary of Product Charasteristics

12 months
after radiolabelling: 8 h

2-8°C
after radiolabelling: ≤ 25°C

For Blood Pool

Table: Cold kits – For Blood Pool

In vivo kit

Product Code

ATC code

Marketing Authorisation No.

For preparation of

Active ingredient

Content/vial

Excipients

Indications

Activity for labelling vial

Vials per kit

Recommended doses

Shelf life

Storage

SPC

PYRON 25 mg

Tc-IK-5

V09BA03

OGYI-T9246/01

Technetium (^99mTc) tin pyrophosphate injection

Sodium pyrophosphate

25.0 mg
- Stannous chloride dihydrate
- Sodium chloride
- Bone and acute myocardial infarct scintigraphy
- Blood pool scintigraphy
- Spleen scintigraphy
1.3–3.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months
after radiolabelling: 3 h

≤ 25°C
after radiolabelling: ≤ 25°C

For Bone Scintigraphy

Table: Cold kits – For Bone Scintigraphy

In vivo kit

Product Code

ATC code

Marketing Authorisation No.

For preparation of

Active ingredient

Content/vial

Excipients

Indications

Activity for labelling vial

Vials per kit

Recommended doses

Shelf life

Storage

SPC

MDP 5 mg

Tc-IK-10

V09BA02

OGYI-T9702/01

Technetium (^99mTc) medronate injection

Medronic acid

5.0 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Urea
For bone scintigraphy (diagnostic skeletal imaging)

Use of the preparation is highly recommended for:
- Primer bone tumours
- Metastases of other tumours, for example prostate/breast/lung cancer
- Osteomyelitis
- Metabolic bone diseases
- Paget’s disease
3.0–6.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months
after radiolabelling: 6 h

2-8°C
after radiolabelling: ≤ 25°C

For Myocardial Perfusion Scintigraphy

Table: Cold kits – For Myocardial Perfusion Scintigraphy

In vivo kit

Product Code

ATC code

Marketing Authorisation No.

For preparation of

Active ingredient

Content/vial

Excipients

Indications

Activity for labelling vial

Vials per kit

Recommended doses

Shelf life

Storage

SPC

MIBITop 1 mg

Tc-IK-81

V09GA01

OGYI-T-23814/01

Technetium (^99mTc) sestamibi injection

[tetrakis (1-isocyanide-2-methoxy-2-methylpropyl-)copper(I)] tetrafluoroborate

1.0 mg
- Cysteine hydrochloride monohydrate
- Sodium citrate
- Stannous chloride dihydrate
- D-Mannitol
- Myocardial perfusion scintigraphy for the detection and localisation of coronary artery disease (angina
  pectoris and myocardial infarction)
- Assessment of global ventricular function.First-pass technique for determination of ejection fraction and/or ECG-triggered, gated SPECT for
  evaluation of left ventricular ejection fraction, volumes and regional wall motion
- Scintimammography for the detection of suspected breast cancer when mammography is equivocal, inadequate
  or indeterminate
- Localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent disease in
  both primary and secondary hyperparathyroidism, and in patients with primary hyperparathyroidism scheduled
  to undergo initial surgery of the parathyroid glands.
max. 15.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months
after radiolabelling: 16 h

2-8°C
after radiolabelling: ≤ 25°C

For Examination of the Liver- and Hepatobiliary System

Table: Cold kits – For Examination of the Liver- and Hepatobiliary System

In vivo kit

Product Code

ATC code

Marketing Authorisation No.

For preparation of

Active ingredient

Content/vial

Excipients

Indications

Activity for labelling vial

Vials per kit

Recommended doses

Shelf life

Storage

SPC

FYTON 15 mg

Tc-IK-2

V09DB07

OGYI-T9288/01

Technetium (^99mTc) phytate injection

Sodium phytate

15.0 mg
- Stannous chloride dihydrate
- Sodium chloride
- Morphological examination of the liver by imaging technique
- Diagnosis of benign and malignant liver tumours and monitoring of the therapy
- Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct,
  etc.)
0.8–1.6 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months
after radiolabelling: 3 h

≤ 25°C
after radiolabelling: ≤ 25°C
TECHIDA 30 mg

Tc-IK-6

V09DA02

OGYI-T-9210/01

Technetium (^99mTc) etifenin injection

Diethyl-acetanilid-imino diacetic acid

30.0 mg
- Stannous chloride dihydrate
- Ascorbic acid
- Dynamic examination of the function of the hepatocytes
- Liver transplant evaluation
- Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct, etc.)
- Examination of the acute cholecystitis
- Diagnosis of focalis nodular hyperplasia
0.8–1.6 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months
after radiolabelling: 6 h

2-8°C
after radiolabelling: 2-8°C

Table: I-131 hard capsules for diagnosis and therapy

Product name

Product code

ATC code

Marketing Auth. No.

Pharmaceutical Form and Description

Activity per capsule

Radionuclidic purity

Radiochemical purity

Expiry time

Indications and Phosology

Storage

Packaging

ThyroTop D 0.5-37 MBq hard capsule complies with the European Pharmacopoeia 0938 monograph

I-RA-7/D

V09F

OGYI-T-9681/05

Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131
labelled sodium iodide, for oral administration.

0.5-37 MBq

¹³¹I ≥ 99.9 %

≥ 95 %

21 days from the manufacturing date
Thyroid diagnostics
- 0.2-0.5 MBq capsule for radioiodine uptake of thyroid in case no accurate dosimetry is
  needed.
- 2-4 MBq capsule can be used for calculation of personalised dose for the radionuclide
  therapy and thyroid scintigraphy for the establishment of the size of the hyperfunctioning
  tissue in thyroid nodules.
- For whole body radioiodine scintigraphy in differentiated thyroid cancer 37-185 MBq
  (usually 74-111 MBq) I-131 is needed. 2-3 capsules should be administered per os.
Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation
safety.

1-10 capsules in type I injection vial, closed with brombutyl stopper and green aluminium cap in lead
container with paper insert.
I-131-sodium-iodide ThyroTop 38-7400 MBq hard capsules complies with the European Pharmacopoeia
2116 monograph

I-RA-7/K

V10XA01

OGYI-T-9681/01

Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131
labelled sodium iodide, for oral administration.

38-7400 MBq

¹³¹I ≥ 99.9 %

≥ 95 %

21 days from the manufacturing date
Radionuclide therapy

Treatment of hyperthyreosis
- Graves disease.
- Hyperfunctioning adenoma.
- Non immunogenic diffuse goiter.
Treatment of thyroid carcinoma
- Ablation of residual thyroid tissues following thyroid cancer surgery and treatment of
  recidivations and metastases.
- Required amount of activity is administered per os in one or max. 2 capsules
Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation
safety.

1 capsule in a plastic insert with screwed cap placed into a lead container with wall thickness of
15-38 mm.

Table: Irradiators

OB-SERVO

Classification

IAEA Category

Storage Type

Source Details

Sealed Source

Maximum Activity

Source Type

Source Dimensions

Source Cage Type

Source Cage Capacity

Configuration

Radiation details

Maximum Central Dose Rate

Dose Uniformity (Max)

Dose Rate at 1 m

Accessories

Pressurized Air Supply

Ventilation System

Water Treatment

Safety and Security System

Control System

Electric Requirements

IGNIS

Research

Category I.

Dry Storage

Co-60

888 TBq
(24 kCi)

CoS-44 HH-N

Ø11×220 mm

Cylindrical

48 pcs

Fixed sources with rotating canister

10 kGy/h

± 20%

–

✓

–

–

✓

✓

50 Hz, 230 V – with ground (Single-Phase Power)
SANGUIS

Research

Category I.

Dry Storage

Co-60

444 TBq
(12 kCi)

CoS-44 HH-N
CoS-45 HH
CoS-57 HH

Ø11×220 mm
Ø11×81.5 mm
Ø23.5×36.5 mm

Cylindrical

8 pcs

Source turn (absorbent unit) and rotating canister

2.5 kGy/h

± 20%

–

–

✓

–

✓

✓

50 Hz, 230 V – with ground (Single-Phase Power)
LA/D

Research and Calibration

Category II.

Dry Storage

Co-60

111 TBq
(3 kCi)

CoS-57 HH

Ø23.5×36.5 mm

Special Drawer

1 pc

Source hoist with collimator and absorbent unit

–

–

30 Gy/h

✓

–

–

✓

✓

50 Hz, 230 V – with ground (Single-Phase Power)
D

Semi – Multipurpose

Category II.

Dry Storage

Co-60

3700 TBq
(100 kCi)

CoS-44 HH-N

Ø11×220 mm

Special Drawer

12 pcs

Source hoist with turntable system

–

–

1 kGy/h

✓

✓

–

✓

✓

50 Hz, 230 V – with ground (Single-Phase Power)
W

Semi – Multipurpose

Category IV.

Wet Storage

Co-60

7400 TBq
(200 kCi)

CoS-43
HH-M
CoS-44 HH-N

Ø11×451 mm,
Ø11×220 mm

Cylindrical

20 pcs

Source hoist with turntable system

–

–

1.5 kGy/h

✓

✓

✓

✓

✓

50 Hz, 230 V – with ground (Single-Phase Power)

Table: I-131 MIBG 20 MBq/ml injection for diagnostic use

Product code

Pharmaceutical form and description

Activity per vial

Specific activity

Radioactive concentration

Radionuclid impurities

Radiochemical purity

pH

Expiry date

Indications and posology

Recommended dose

Storage

Packaging

I-RAO-1

Radioactive sterile injection solution.
The active ingredient of the radioactive solution for
injection for intravenous use is I-131 radioisotope labelled meta-iodobenzyl-guanidine (MIBG).

20 MBq, 40 MBq, or 80 MBq at activity reference date and time

≥ 26.7 GBq/g MIBG at activity reference date and time

20 MBq/ml at activity reference date and time

≤ 0.1%

≥ 95%

5–7

5 days from manufacturing date

Indication field: radioisotope diagnostics
Localisation and imaging of neuroendocrine tumours, especially:phaeochromocytomaneuroblastoma

The recommended individual patient dose is 20–40 MBq I-131-MIBG

To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended
before the examination. The injection should be administered slowly; time of administration is 2-4
minutes.

Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or
asthmatic spasms.

Store in refrigerator at 2–8°C. Comply with the regulations for radiation safety.

In type I injection vial (6R) closed with brombutyl stopper and green aluminium cap in lead container
with paper insert.

Transported in a Type A package

Table: I-131 MIBG 370 MBq/ml injection for therapy

Product code

Pharmaceutical form and description

Activity per vial

Specific activity

Radioactive concentration

Radionuclid impurities

Radiochemical purity

pH

Expiry date

Indications and posology

Recommended dose

Storage

Packaging

I-RAO-2

Radioactive sterile solution for injection.

For intravenous use. The active ingredient of the radioactive solution for injection for intravenous
use is I-131 radioisotope labelled meta-iodobenzylguanidine (MIBG)

3300-4100 MBq at activity reference date and time

≥ 555 GBq/g at activity reference date and time

333-410 MBq/ml at activity reference date and time

≤ 0.1%

≥ 90%

5-5.5

5 days from manufacturing date
RADIOISOTOPE THERAPY

Local, lesion-specific treatment of neuro-endocrine tumours, especially:
- phaeochromocytoma
- neuroblastoma
- paraganglioma
- medullar thyroid carcinoma
- carcinoid
The recommended individual dose is 3.3–4.1 GBq.

To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended
before the examination.

Do not administer the injection directly. 10 ml of the MIBG solution for injection must be mixed with
90 ml of 5% glucose injection. The obtained solution which has a total volume of 100 ml should be
administered to the patient slowly. Time of administration is 2 – 4 hours.

Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or
asthmatic spasms.

Store in a freezer, below -18°C. Storage of radiopharmaceuticals should be in accordance with
national regulation on radioactive material. To ensure the low temperature during shipping dry-ice
is used to cool the container.

In type I injection vial (10R), closed with brombutyl stopper and green aluminium cap in lead
container with paper insert.

Transported in a Type A package

Table: I-131 sodium iodide solutions, drug substances supported with Active Substance Master File

Product name

Product code

Description

Volume

Radioactive concentration

Radionuclidic purity

Radiochemical purity

pH

Expiry time

Other information

Storage

Packaging

I-131 sodium iodide sterile solution, drug substance according to European Pharmacopoeia 0281
monograph

I-RA-7

Clear, colourless and sterile solution of 131I sodium iodide containing iodine-131 in the form of
sodium idoide in Na2CO3/NaHCO3/NaOH buffer and 0.5-2 mg/ml sodium thiosulphate solution, reducing
agent diluted accoring to the cusomer specified active concentration. Bacterial endotoxins <100
IU/ml.

Non-carrier added

0.2 – 10.0 ml

0.1 – 55.5 GBq/ml

¹³¹I ≥ 99.9 %

≥ 95 %

7 – 10

21 days from manufacturing date

Active pharmaceutical ingredient for manufacture of radiopharmaceuticals by dilution with water or by
for capsule preparation.

For oral administration.

Store at room temperature in its own container, in accordance with the regulations on radioactive
materials.

In type I injection vial (6R or 10 R), closed with brombutyl stopper and green aluminium cap in lead
container with paper insert (Type A packaging).

Pack size: ≤ 29.6 GBq (at the indicated calibration date)/vial
I-131 sodium iodide non-sterile solution, drug substance for radiolabelling according to European
Pharmacopoeia 02121 monograph

I-RA-5

Clear, colourless and non-sterile solution of 131I sodium iodide containing iodine-131 in the form of
sodium iodide in Na2CO3/NaHCO3/NaOH buffer diluted with 0.0001M NaOH according to the customer
specified active concentration.

Non-carrier added. No reducing agents added.

0.2 – 10.0 ml

≥ 0.1-55.5 GBq/ml

¹³¹I ≥ 99.9 %

≥ 95 %

8 – 11

21 days from manufacturing date

Active ingredient for manufacture of radiopharmaceuticals by dilution – e.g. with water or buffer for
labelling purposes or capsule preparation, for oral administration.

Store at room temperature in its own container, in accordance with the regulations on radioactive
materials.

In type I injection vial (6R or 10 R), closed with brombutyl stopper and green aluminium cap in lead
container with paper insert (Type A packaging).

Pack size: ≤ 111 GBq (at the indicated calibration date)/vial

Table: I-125 Radiochemicals

Product code

Description

Specific activity

Radioactive concentration

Radionuclid impurities

Radiochemical purity

pH

Calibration date

Expiry date

Storage

Packaging

I-RB-4

Clear, colourless solution containing I-125 sodium iodide in NaOH. Non-carrier added. No reducing agents added

≥ 600 GBq/mg

≤ 3669 MBq/ml

I-126 ≥ 0.005%

≥ 95%

8 – 11

13 days

60 days from dispatch

Store at room temperature in its own container, in accordance with the regulations on radioactive materials.

Supplied in plastic vial placed in a lead container (KT 1-3).

The lead container is packed in a labelled easy-open metal can, which contains plastic insert.

Transported in a Type A packaging in accordance with IATA regulation.
I-RB-41

Clear, colourless solution containing I-125 sodium iodide in NaOH. Non-carrier added. No reducing agents added

≥ 600 GBq/mg

≥ 3700 MBq/ml

I-126 ≥ 0.005%

≥ 95%

8 – 11

13 days

60 days from dispatch

Store at room temperature in its own container, in accordance with the regulations on radioactive materials.

Supplied in plastic vial placed in a lead container (KT 1-3).

The lead container is packed in a labelled easy-open metal can, which contains plastic insert.

Transported in a Type A packaging in accordance with IATA regulation.

Table: Distributed Products

SPECIFICATIONS

Standards

Density Measurement Range

Moisture Measurement Range

Density Source

Moisture Source

Density Source Activity

Moisture Source Activity

PRECISION

BS one-minute test

Transmission one-minute test

Moisture one-minute test

CHEMICAL COMPOSITION ERROR

Backscatter

Transmission

SURFACE ROUGHNESS ERROR (0.05 in. 100% void)

Backscatter

Transmission

OPERATING TEMPERATURE

Ambient

Surface

Power Source

Battery Life

Display

Memory Storage

Gauge Size

Weight

Shipping Weight

ASTM D6938, D2950, D7013, D7759, C1040 and AASHTO T310

70 to 170 pcf
(1.120 to 2.73 gcc)

0 to 40 pcf (0 to 0.64 gcc)

Cesium 137

Americium 241: Beryllium

Maximum (10 mCi) 370 Mbq

Maximum (50 mCi) 1.85 GBq

±0.50 pcf (0.008 gcc)(at 125 pcf)

±0.25 pcf (0.004 gcc)(at 125 pcf)

±0.25 pcf (0.004 gcc)(at 10 pcf)

±1.00 pcf (0.016 gcc)

±0.75 pcf (0.012 gcc)

– 4.00 pcf (0.064 gcc)

– 0.50 pcf (0.008 gcc)

– 14° to 167°F (-10° to 75°C)

Up to 350°F (175°C)

6-Cell AA NiMH battery pack with a single 9V alkaline for backup

500-1000 recharge/discharge cycles

Large 4 line X 20 character LCD display with 9mm tall characters

10 Projects with 40 readings each

26.7″ H X 14.1″ W X 9.8″ D
(67.8 x 35.8 x 24.8 cm)

28.5 lbs (13 kg)

90 lbs (40.82 kg)

Table: Immunoassay – Tumour Markers

Product code

Product name

Pack size (Test)

IFU/EN

IFU/ES

IFU/RU

RK-800CT

AFP [I-125] IRMA KIT

[100]
RK-760CT

ßhCG [I-125] IRMA KIT

[100]
RK-820CT

free ßhCG [I-125] IRMA KIT

[100]
RK-38CT

hCEA [I-125] IRMA KIT

[100]
RK-10CT

hPSA [I-125] IRMA KIT

[100]
RK-85CT

free PSA [I-125] IRMA KIT

[100]
RK-125CT

CA125 [I-125] IRMA KIT

[100]
RK-199CT

CA 19-9 [I-125] IRMA KIT

[100]
RK-153CT

CA 15-3 [I-125] IRMA KIT

[100]
RK-724CT

CA 72-4 [I-125] IRMA KIT

[100]
RK-211CT

CYFRA 21.1 IRMA KIT

[100]
RK-300CT

NSE [I-125] IRMA kit *

[100]

* =on request product / minimum order: 5 kits

Table: Immunoassay – Diabetes

Product code

Product name

Pack size (Test)

IFU/EN

IFU/ES

IFU/RU

RK-84CT

hC-peptide [I-125] IRMA KIT

[100]
RK-400CT

INSULIN [I-125] IRMA KIT

[100]
RK-20P100

Anti-IA2 RIA KIT

[100]
RK-40P100

Anti-GAD65 RIA KIT

[100]
RK-50P100

IAA RIA KIT

[100]
RK-20P50

Anti-IA2 RIA KIT

[50]
RK-40P50

Anti-GAD65 RIA KIT

[50]
RK-50P50

IAA RIA KIT

[50]

Table: Immunoassay – Thyroid Functions

Product code

Product name

Pack size (Test)

IFU/EN

IFU/ES

IFU/RU

RK-83CT

hCalcitonin [I-125] IRMA KIT

[100]
RK-8CT

Anti-hTG [I-125] RIA KIT

[100]
RK-51CT

hTG [I-125] IRMA KIT

[100]
RK-36CT

Anti-hTPO [I-125] RIA KIT

[100]
RK-1CT1

Turbo TSH [I-125] IRMA KIT

[100]
RK-1CT5

Turbo TSH [I-125] IRMA KIT

[500]
RK-339CT

FT3 [I-125] RIA KIT

[100]
RK-349CT

FT4 [I-125] RIA KIT

[100]
RK-11CT1

T4 [I-125] RIA KIT

[100]
RK-609CT

T3 [I-125] RIA KIT

[100]
RK-950CT

T3 UPTAKE [I-125] RIA KIT

[100]

Table: Immunoassay – Steroid Hormones

Product code

Product name

Pack size (Test)

IFU/EN

IFU/ES

IFU/RU

RK-460CT

PROGESTERONE [I-125] RIA KIT

[100]
RK-61CT

TESTOSTERONE [I-125] RIA KIT

[100]
RK-240CT

CORTISOL [I-125] RIA KIT

[100]
RK-620CT

DHEA-SO4 [I-125] RIA KIT

[100]

Table: Immunoassay – Serum Proteins

Product code

Product name

Pack size (Test)

IFU/EN

IFU/ES

IFU/RU

RK-5CT

hGH [I-125] IRMA KIT

[100]
RK-750CT

hLH [I-125] IRMA KIT

[100]
RK-780CT

hPRL [I-125] IRMA KIT

[100]
RK-790CT

hFSH [I-125] IRMA KIT

[100]
RK-4CT

PAPP-A [I-125] IRMA kit

[100]
RK-86CT

SHBG [I-125] IRMA KIT

[100]
RK-900CT

FERRITIN [I-125] IRMA KIT

[100]

Table: Radiation Protection Systems – HK Marked Group of Products

Sign

Activity of the
Transportable Material (Co-60)
[GBq]

Inner Size of the
Storage Unit
[mm]

Weight of Package
Container/Package/Gross
[kg]

HK-5

5

50 x 50

70/145/215
HK-10

10

50 x 150

230/140/370
HK-40

40

50 x 150

420/140/560
HK-400

400

80 x 150

640/135/775

Table: Other Labelled Products – Carbon-14

Code

Product
specific activity: 370 – 1850 MBq /mmol

Unlabelled
CAS number

CC-502

N-Acetyl-2-chloro-[U-¹⁴C]aniline

533-17-5
CC-501

N-Acetyl-2-nitro-[U-¹⁴C]aniline

552-32-9
CC-509

[U-¹⁴]Benzenesulfonyl chloride

98-09-9
CC-563

1,3-Bis(4-nitro-[U-¹⁴]phenyl)urea; DNC, [ring-U-¹⁴]

587-90-6
CC-566

4-Bromo-N,N-dimethyl-[U-¹⁴C]aniline

586-77-6
CC-528

i-[1-¹⁴C]Butyric acid hydrazide

3619-17-8
CC-543

4-Chloro-[ring-U-¹⁴C]benzoic acid

74-11-3
CC-439

Copper(I) [¹⁴C]cyanide

544-92-3
CC-591

[2-¹⁴C]Cyclohexane-1,3-dione

504-02-9
CC-590

3,4-Dichloro-[U-¹⁴C]aniline

95-76-1
CC-507

2,4′-Dichloro-[carbonyl-¹⁴C]benzophenone

85-29-0
CC-511

2,4′-Dichloro-[4′-chlorophenyl-U-¹⁴C]benzophenone

85-29-0
CC-592

[1,2-¹⁴C]Dichloroethane

107-06-2
CC-521

2,5-Dichloro-[U-¹⁴C]phenol

583-78-8
CC-506

3,4-Dimethyl-[U-¹⁴C]aniline

95-64-7
CC-520

4-Fluoro-[ring-U-¹⁴C]acetanilide

351-83-7
CC-564

2-Hydroxy-4,6-dimethyl-[2-¹⁴C]pyrimidine; HDP, [2-¹⁴C]

108-79-2
CC-595

4-Iodo-nitro[U-¹⁴C]benzene

636-98-6
CC-508

[2-¹⁴C]Isopropyl-triphenyl-phosphonium iodide

24470-78-8
CC-515

Medetomidine, [imidazole-2-¹⁴C]

86347-14-0
CC-517

Medetomidine, [phenyl U-¹⁴C]

86347-14-0
CC-561

4-Methyl-[ring-U-¹⁴C]acetophenone

122-00-9
CC-513

Methyl 2-pyrimidine[¹⁴C]carboxylate

34253-03-7
CC-519

[carboxyl-¹⁴C]Nicotinic acid

59-67-6
CC-594

2-Nitro-[U-¹⁴C]aniline

88-74-4
CC-518

4-Nitro-[U-¹⁴C]aniline

100-01-6
CC-505

4-Nitro-[formyl-¹⁴C]benzaldehyde

555-16-8
CC-18

4-Nitro-[U-¹⁴C]phenol

100-02-7
CC-237

Phenyl-[1-¹⁴C]acetic acid

103-82-2
CC-471

2-Phenyl-[1-¹⁴C]propionic acid

492-37-5
CC-461

2-[ring-U-¹⁴C]Phenylpropionic acid

492-37-5
CC-510

Potassium [¹⁴C]thiocyanate

333-20-0
CC-523

Sulfadiazine, [phenyl ring-U-¹⁴C]

68-35-9
CC-476

Sulfamethoxazole, [phenyl ring-U-¹⁴C]

723-46-6
CC-195

[1,4-¹⁴C]Succinic acid

110-15-6
CC-468

Tilmicosin, [3,5-dimethylpiperidin-1-yl-3,5-¹⁴C]

108050-54-0
CC-522

4-[ring-U-¹⁴C]Toluic acid

99-94-5
CC-495

1,2,4-Trichloro-[U-¹⁴C]benzene

120-82-1
CC-553

Triethyl phosphono[1-¹⁴C]acetate

867-13-0
CC-499

2-Trifluoromethyl-[ring-U-¹⁴C]benzoic acid

433-97-6
CC-361

Troglitazone, [thiazolidin-2,4-dione 2-¹⁴C]

97322-87-7
CC-426

Zinc [¹⁴C]cyanide

557-21-1

Table: Research immunoassay kits – Rat Hormones

Code

Test

Pack Size (Tests)

IFU

RK-547

rInsulin RIA kit *

120
RK-547CT

rInsulin IRMA kit coated tube version

100
EK-547

rInsulin ELISA kit

96
RK-548

rCorticosterone RIA kit

120
RK-548CT

rCorticosterone RIA kit coated tube version

100
EK-548

rCorticosterone ELISA kit

96
RK-550

rFSH (rat follicle stimulating hormone) RIA kit

120
RK-551

rGH (rat growth hormone) RIA kit

120
RK-552

rLH (rat luteinizing hormone) RIA kit

120
RK-553

rPRL (rat prolactin) RIA kit*

120
RK-554

rTSH (rat thyroid stimulating hormone) RIA kit

120
RK-554Cset

rTSH (rat thyroid stimulating hormone) RIA kit Control set

–
EK-547Cset

rInsulin ELISA kit Control set

–

*On request

List of scientific publications HERE

Table: Research immunoassay kits – Human Research Kits

Code

Test

Pack Size (Tests)

IFU

RK-509

cAMP (adenosine 3′,5′-cyclic monophosphate) RIA kit*

100
RK-512

αANP (human α-atrial natriuretic peptide) RIA kit *

100
RK-518

C3a (human complement C3a des Arg) RIA kit

150
RK-518Cset

C3a (human complement C3a des Arg) RIA kit Control set
RK-519

C4a (human complement C4a des Arg) RIA kit

150
RK-519Cset

C4a (human complement C4a des Arg) RIA kit Conrol set
RK-520

C5a (human complement C5a des Arg) RIA kit

150
RK-525

cGMP (guanosine 3′,5′-cyclic monophosphate) RIA kit*

100
RK-535

Endothelin-1,2 RIA kit *

100
RK-545

Endothelin-1,2 high sensitivity RIA kit *

100
RK-555

Endothelin 1-21 RIA kit *

100

* On request

Table: Research immunoassay kits – Human IVD kits useful for Animal Science Research

Bovine

Ovine

Caprine

Equine

Porcine

Rabbit

Rodents

Poultry

Monkey

Fish

Thyroid hormones

RK-609CT, RK-339CT, RK-11CT1, RK-349CT

Click here

Click here

Click here

Click here

Click here

Click here

Click here

Click here
Progesterone

RK-460CT

Click here

Click here

Click here

Click here

Click here

Click here
Testosterone

RK-61CT

Click here

Click here

Click here

Click here

Click here
Cortisol

RK-240CT

Click here

Click here

Click here

Click here

Click here

Click here

List of scientific publications HERE